On February 19, the day after French authorities present a landmark pricing and reimbursement draft to industry stakeholders, Cannabis Europa Paris 2026 will open its doors at Hôtel de l’Industrie, bringing the details directly to the global cannabis industry.
French authorities are set to present the first draft of the country’s long-awaited medical cannabis pricing and reimbursement decree on February 18, in a private consultation meeting with industry stakeholders organised by the Direction Générale de la Santé (DGS) and the Direction de la Sécurité Sociale (DSS). The decree is widely regarded as the final regulatory obstacle standing between France and a fully operational medical cannabis market.
The following morning, Cannabis Europa Paris 2026 will open at Hôtel de l’Industrie in Paris, and the conference will begin by placing those freshly published details directly in front of the global industry. The conference will feature direct political representation, with MP Camille Galliard-Minier delivering the opening keynote on France’s legislative roadmap, MP Jean-Pierre Cubertafon joining the session presenting the full results of the 2021–2025 pilot programme. Their presence signals the degree to which France’s medical cannabis transition has moved from the margins of policy debate to the centre of parliamentary attention.
Ludovic Rachou, President of French medical cannabis trade organisation UIVEC, confirmed that the February 18 meeting „will mark the launch of the consultation process on the last missing regulatory text for the generalisation of medical cannabis in France.“
„While this version will still be subject to comments and adjustments, it will provide, for the first time, a concrete view of the economic and reimbursement model envisaged by the French government,“ Rachou said. The Haute Autorité de Santé (HAS), which paused its evaluation work in December 2025 after concluding it could not finalise reimbursement structures without the published decree, is expected to resume its assessment once the decree is formally
adopted. From what UIVEC has gathered, the authorities intend to ensure HAS delivers a positive evaluation of cannabis-based medicines, meaning reimbursement itself should not be in question. However, as Rachou has made clear: „Reimbursement without pricing doesn’t mean anything. If the price is not viable, then no one will come on the market.“
- Beyond the regulatory opening, Cannabis Europa Paris 2026 will host a full day of expert-led sessions examining every dimension of France’s transition from pilot programme to national system. The programme includes:
- An opening keynote from MP Camille Galliard-Minier on France’s roadmap from pilot to full policy, covering permanent access pathways, prescriber obligations, the evolving role of pharmacies, and the financial and regulatory pressures that will define the next phase of reform.
- A deep-dive session presenting the full results of the 2021–2025 pilot programme and analysing the first months of generalisation, with speakers including MP Jean-Pierre Cubertafon.
- A panel on domestic production at scale, „Made in France“, examining what it takes to build a national supply chain that reflects France’s pharmaceutical tradition and agricultural strength, featuring producers including Demecan and PGP Farmer.
- International benchmarking panels drawing on a decade of Canadian data (featuring Tilray and Avicanna) and lessons from Luxembourg and Switzerland.
- Cannabis Europa Paris 2026 takes place on February 19 at Hôtel de l’Industrie, Paris. Registration and the full programme are available at cannabis-europa.com.
About Cannabis Europa
Cannabis Europa is Europe’s leading conference series for the regulated cannabis industry, bringing together policymakers, clinicians, investors, producers, and operators to advance evidence-based policy and commercial development across the continent.
Disclaimer: This article is part of a media partnership. We are media partner of Cannabis Europa Paris at 19th of February 2026. Readers get 10% discount with the code: MEDIA10.